Literature DB >> 1672251

c-erbB-2 oncogene as a prognostic marker in breast cancer.

T J Perren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1672251      PMCID： PMC1971858          DOI： 10.1038/bjc.1991.78

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  44 in total

1.  Cathepsin D and prognosis in breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; J M Chirgwin; W L McGuire
Journal:  N Engl J Med       Date:  1990-02-01       Impact factor: 91.245

2.  HER-2/neu amplification predicts poor survival in node-positive breast cancer.

Authors:  A Borg; A K Tandon; H Sigurdsson; G M Clark; M Fernö; S A Fuqua; D Killander; W L McGuire
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

3.  c-erbB-2 protein expression in node negative breast cancer.

Authors:  J Richner; H A Gerber; G W Locher; A Goldhirsch; R D Gelber; W J Gullick; M S Berger; B Groner; N E Hynes
Journal:  Ann Oncol       Date:  1990-07       Impact factor: 32.976

4.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

Authors:  S Paik; R Hazan; E R Fisher; R E Sass; B Fisher; C Redmond; J Schlessinger; M E Lippman; C R King
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

5.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer.

Authors:  C Lovekin; I O Ellis; A Locker; J F Robertson; J Bell; R Nicholson; W J Gullick; C W Elston; R W Blamey
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

6.  The long term prognostic significance of c-erbB-2 in primary breast cancer.

Authors:  J Winstanley; T Cooke; G D Murray; A Platt-Higgins; W D George; S Holt; M Myskov; A Spedding; B R Barraclough; P S Rudland
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

7.  The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.

Authors:  S M O'Reilly; D M Barnes; R S Camplejohn; J Bartkova; W M Gregory; M A Richards
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

8.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.

Authors:  W J Gullick; S B Love; C Wright; D M Barnes; B Gusterson; A L Harris; D G Altman
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

9.  Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression.

Authors:  E May; H Mouriesse; F May-Levin; J F Qian; P May; J C Delarue
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

10.  A prognostic index in primary breast cancer.

Authors:  J L Haybittle; R W Blamey; C W Elston; J Johnson; P J Doyle; F C Campbell; R I Nicholson; K Griffiths
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640
View more
  36 in total

1.  Clinical and Histological Prognostic Factors in Axillary Node-Negative BreastCancer: Univariate and Multivariate Analysis with Relation to 5-Year Recurrence.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

2.  Prognostic significance of c-erb-B2 amplification in fine-needle biopsies of breast cancer patients not operated at diagnosis.

Authors:  U Lönn; S Lönn; B Nilsson; B Stenkvist
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

4.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 5.  Molecular biology of breast carcinoma.

Authors:  D el-Ashry; M E Lippman
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

6.  Bimodal gene expression patterns in breast cancer.

Authors:  Marina Bessarabova; Eugene Kirillov; Weiwei Shi; Andrej Bugrim; Yuri Nikolsky; Tatiana Nikolskaya
Journal:  BMC Genomics       Date:  2010-02-10       Impact factor: 3.969

7.  Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters.

Authors:  A Piffanelli; R Dittadi; L Catozzi; M Gion; G Capitanio; M C Gelli; A Brazzale; R Malagutti; D Pelizzola; A Menegon; G Giovannini; G Gardini
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer.

Authors:  I Brotherick; B K Shenton; W K Cowan; B Angus; C H Horne; M J Higgs; T W Lennard
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

9.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.

Authors:  C C Benz; G K Scott; J C Sarup; R M Johnson; D Tripathy; E Coronado; H M Shepard; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  Phosphotyrosine signaling proteins that drive oncogenesis tend to be highly interconnected.

Authors:  Grigoriy Koytiger; Alexis Kaushansky; Andrew Gordus; John Rush; Peter K Sorger; Gavin MacBeath
Journal:  Mol Cell Proteomics       Date:  2013-01-28       Impact factor: 5.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.